ES2453161T3 - Sistema de ensayo para la evaluación de la oncogenicidad, progresión tumoral y eficacia de un tratamiento - Google Patents

Sistema de ensayo para la evaluación de la oncogenicidad, progresión tumoral y eficacia de un tratamiento Download PDF

Info

Publication number
ES2453161T3
ES2453161T3 ES09704611.4T ES09704611T ES2453161T3 ES 2453161 T3 ES2453161 T3 ES 2453161T3 ES 09704611 T ES09704611 T ES 09704611T ES 2453161 T3 ES2453161 T3 ES 2453161T3
Authority
ES
Spain
Prior art keywords
decrease
sample
apoptosis
tissue
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09704611.4T
Other languages
English (en)
Spanish (es)
Inventor
Niven Rajin Narain
Indushekhar Persaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytotech Labs LLC
BERG LLC
Original Assignee
Cytotech Labs LLC
BERG LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytotech Labs LLC, BERG LLC filed Critical Cytotech Labs LLC
Application granted granted Critical
Publication of ES2453161T3 publication Critical patent/ES2453161T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
ES09704611.4T 2008-01-25 2009-01-26 Sistema de ensayo para la evaluación de la oncogenicidad, progresión tumoral y eficacia de un tratamiento Active ES2453161T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2357008P 2008-01-25 2008-01-25
US23570P 2008-01-25
PCT/US2009/031957 WO2009094619A1 (en) 2008-01-25 2009-01-26 Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy

Publications (1)

Publication Number Publication Date
ES2453161T3 true ES2453161T3 (es) 2014-04-04

Family

ID=40901454

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09704611.4T Active ES2453161T3 (es) 2008-01-25 2009-01-26 Sistema de ensayo para la evaluación de la oncogenicidad, progresión tumoral y eficacia de un tratamiento
ES13192129.8T Active ES2589506T3 (es) 2008-01-25 2009-01-26 Sistema de ensayo para la evaluación de la oncogenicidad, progresión tumoral y eficacia de un tratamiento

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13192129.8T Active ES2589506T3 (es) 2008-01-25 2009-01-26 Sistema de ensayo para la evaluación de la oncogenicidad, progresión tumoral y eficacia de un tratamiento

Country Status (7)

Country Link
US (1) US10365279B2 (enExample)
EP (2) EP2245460B1 (enExample)
JP (3) JP2011511271A (enExample)
KR (2) KR101711860B1 (enExample)
AU (1) AU2009206289A1 (enExample)
ES (2) ES2453161T3 (enExample)
WO (1) WO2009094619A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
KR101765999B1 (ko) 2015-01-21 2017-08-08 서울대학교산학협력단 암 바이오마커의 성능 평가 장치 및 방법
CA3126432A1 (en) * 2019-02-01 2020-08-06 Health Research, Inc. Methods and compositions for treating resistant and recurrent forms of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19736691A1 (de) 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
AU2002216009A1 (en) 2000-11-03 2002-05-15 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
US20030138792A1 (en) * 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
CN102402650A (zh) 2001-11-09 2012-04-04 生命技术公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
FR2840923B1 (fr) 2002-06-17 2007-07-06 Centre Nat Rech Scient Agent anti-resistance a l'oxaliplatine
WO2003106974A2 (en) 2002-06-18 2003-12-24 Irm Llc Diagnosis and treatment of chemoresistant tumors
EP1507148B1 (en) 2003-08-25 2005-02-23 MTM Laboratories AG Method for detecting carcinomas in a solubilized cervical body sample
CA2561513C (en) 2004-03-29 2019-02-26 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
WO2005103281A2 (en) * 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
WO2006022895A2 (en) 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
EP2302388A1 (en) * 2004-10-14 2011-03-30 Genentech, Inc. COP1 molecules and uses thereof
WO2007137187A2 (en) * 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state

Also Published As

Publication number Publication date
JP2011511271A (ja) 2011-04-07
JP2015052605A (ja) 2015-03-19
JP2017102125A (ja) 2017-06-08
EP2245460A1 (en) 2010-11-03
EP2708894A3 (en) 2014-04-02
EP2708894B1 (en) 2016-07-06
AU2009206289A1 (en) 2009-07-30
KR101711860B1 (ko) 2017-03-03
WO2009094619A1 (en) 2009-07-30
EP2245460A4 (en) 2011-05-25
EP2245460B1 (en) 2013-12-25
US20110027811A1 (en) 2011-02-03
EP2708894A2 (en) 2014-03-19
KR20100131435A (ko) 2010-12-15
ES2589506T3 (es) 2016-11-14
US10365279B2 (en) 2019-07-30
KR101714359B1 (ko) 2017-03-09
HK1150401A1 (en) 2011-12-23
KR20150123344A (ko) 2015-11-03
JP6087888B2 (ja) 2017-03-01

Similar Documents

Publication Publication Date Title
ES2589506T3 (es) Sistema de ensayo para la evaluación de la oncogenicidad, progresión tumoral y eficacia de un tratamiento
Selvarajah et al. Prognostic and predictive biomarkers of canine osteosarcoma
Dong et al. The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma
Chen et al. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma
Tetikkurt et al. Coexistence of adenomyosis, adenocarcinoma, endometrial and myometrial lesions in resected uterine specimens
Haupt et al. Deconstruction of p53 functions and regulation
Janša et al. Proteomic analysis of peritoneal fluid identified COMP and TGFBI as new candidate biomarkers for endometriosis
Kutomi et al. Current status of the prognostic molecular biomarkers in breast cancer: A systematic review
Pontikaki et al. Endometriosis and breast cancer: A survey of the epidemiological studies
Kondo et al. Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor
El-Shazly et al. The role of β-catenin and paired-like homeobox 2B (PHOX2B) expression in neuroblastoma patients; predictive and prognostic value
Carlson et al. Biomarkers in melanoma: staging, prognosis and detection of early metastases
Bastu et al. Distinguishing the progression of an endometrioma: Benign or malignant?
Hoorshad et al. What are the determinants of parametrial invasion in patients with early stage cervical cancer: A cross sectional study
Kim et al. Prevalence of the CTNNB1 mutation genotype in surgically resected fibromatosis of the breast
Jama et al. Altered nuclear expression of the deubiquitylase BAP1 cannot be used as a prognostic marker for canine melanoma
ES2876038T3 (es) Método, aparato y kit para la detección temprana de cáncer de mama
AU2015203304B2 (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
Udiyanto et al. A cohort study: caspase-3 as prognostic factor of radiation therapy in the advanced stage of cervical cancer (IIB-IIIB) patients
Cuk et al. Surgical stress response and long-term survival in robot-assisted versus laparoscopic surgery for colon cancer: a propensity matched nationwide cohort study
Sahoo et al. Relationship between molecular markers and treatment response in a retrospective cohort of Indian patients with primary carcinoma of the larynx
Chen et al. Immunohistochemical expression of Ki67, CD10, BRAF, and α-SMA tumour markers in ameloblastoma and odontogenic keratocyst
HK1195623A (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
HK1150401B (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
HK1195623B (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy